Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Information for Advertisers
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Editor Picks
    • Blogging Stroke
    • AHA/ASA Guidelines and Statements
    • ISC and Nursing Symposium Abstracts
    • Progress and Innovation Award Recipients
    • Acknowledgment of Reviewers
    • Stroke in Women
    • Outstanding Reviewers 2017
  • Resources
    • Online Submission/Peer Review
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • → Tips for Submission
    • → Links and Forms
    • → Revised Manuscripts
    • Costs to Authors
    • Journal Policies
    • Wolters Kluwer Author Services
    • Early Career Resources
    • Stroke CME
    • Webinar Series
    • Permissions and Rights Q&A
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Stroke

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Information for Advertisers
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Editor Picks
    • Blogging Stroke
    • AHA/ASA Guidelines and Statements
    • ISC and Nursing Symposium Abstracts
    • Progress and Innovation Award Recipients
    • Acknowledgment of Reviewers
    • Stroke in Women
    • Outstanding Reviewers 2017
  • Resources
    • Online Submission/Peer Review
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • → Tips for Submission
    • → Links and Forms
    • → Revised Manuscripts
    • Costs to Authors
    • Journal Policies
    • Wolters Kluwer Author Services
    • Early Career Resources
    • Stroke CME
    • Webinar Series
    • Permissions and Rights Q&A
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Original Contribution

Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy

The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

Thompson G. Robinson, Xia Wang, Hisatomi Arima, Philip M. Bath, Laurent Billot, Joseph P. Broderick, Andrew M. Demchuk, Geoffery A. Donnan, Jong S. Kim, Pablo M. Lavados, Tsong-Hai Lee, Richard I. Lindley, Sheila C. O. Martins, Veronica V. Olavarria, Jeyaraj D. Pandian, Mark W. Parsons, Octavio M. Pontes-Neto, Stefano Ricci, Shoichiro Sato, Vijay K. Sharma, Thang H. Nguyen, Ji-Guang Wang, Mark Woodward, John Chalmers, Craig S. Anderson
and on behalf of the ENCHANTED Investigators
Download PDF
https://doi.org/10.1161/STROKEAHA.116.016274
Stroke. 2017;48:1877-1883
Originally published June 15, 2017
Thompson G. Robinson
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xia Wang
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisatomi Arima
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip M. Bath
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Billot
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph P. Broderick
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew M. Demchuk
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffery A. Donnan
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jong S. Kim
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo M. Lavados
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsong-Hai Lee
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard I. Lindley
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheila C. O. Martins
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronica V. Olavarria
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeyaraj D. Pandian
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark W. Parsons
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Octavio M. Pontes-Neto
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Ricci
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoichiro Sato
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vijay K. Sharma
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thang H. Nguyen
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ji-Guang Wang
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Woodward
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Chalmers
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig S. Anderson
From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People’s Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
Loading

Abstract

Background and Purpose—Many patients receiving thrombolysis for acute ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study).

Methods—Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset, 752 (22.9%) reported prior APT use. Primary outcome at 90 days was the combined end point of death or disability (modified Rankin Scale [mRS] scores, 2–6). Other outcomes included mRS scores 3 to 6, ordinal mRS shift, and symptomatic intracerebral hemorrhage by various standard criteria.

Results—There were no significant differences in outcome between patients with and without prior APT after adjustment for baseline characteristics and management factors during the first week; defined by mRS scores 2 to 6 (adjusted odds ratio [OR], 1.01; 95% confidence interval [CI], 0.81–1.26; P=0.953), 3 to 6 (OR, 0.95; 95% CI, 0.75–1.20; P=0.662), or ordinal mRS shift (OR, 1.03; 95% CI, 0.87–1.21; P=0.770). Alteplase-treated patients on prior APT had higher symptomatic intracerebral hemorrhage (OR, 1.82; 95% CI, 1.00–3.30; P=0.051) according to the safe implementation of thrombolysis in stroke-monitoring study definition. Although not significant (P-trend, 0.053), low-dose alteplase tended to have better outcomes than standard-dose alteplase in those on prior APT compared with those not using APT (mRS scores of 2–6; OR, 0.84; 95% CI, 0.62–1.12 versus OR, 1.16; 95% CI, 0.99–1.36).

Conclusions—Low-dose alteplase may improve outcomes in thrombolysis-treated acute ischemic stroke patients on prior APT, but this requires further evaluation in a randomized controlled trial.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01422616.

  • aspirin
  • brain infarction
  • hypertension
  • intracranial hemorrhages
  • tissue plasminogen activator

Introduction

See related article, p 1720

Intravenous alteplase (recombinant tissue plasminogen activator) is the only approved medical reperfusion treatment in patients with acute ischemic stroke (AIS); and the earlier the treatment is given, the greater the proportional benefit.1 Because ≤40% of AIS patients have regularly taken antiplatelet therapy (APT), mainly aspirin, at the time of intravenous alteplase,2–4 a harmful interaction between these 2 agents may reduce the net benefit of thrombolysis treatment. Two recent meta-analyses of randomized controlled trials and cohort studies have both reported that APT use at the time of alteplase significantly increases the risk of symptomatic intracerebral hemorrhage (sICH).5,6 Pan et al6 reported that his was associated with a reduced probability of good outcome (odds ratio [OR], 0.86; 95% confidence interval [CI], 0.73–1.01; P=0.06), although others have not reported any clear attenuation of the clinical benefit.7 However, the ARTIS trial (APT in Combination With Recombinant Tissue Plasminogen Activator in Thrombolysis in Ischemic Stroke), the only randomized trial of de novo aspirin with standard-dose alteplase versus standard-dose alteplase alone, was terminated prematurely because of an excess sICH in the combination arm (absolute difference, 2.8%; 95% CI, 0.2–5.4; P=0.04).8

Concerns over the risk of sICH with intravenous alteplase have led to lower doses being used in many AIS patient groups, particularly Asians,9 after a dose of 0.6 mg/kg was approved for use in Japan. The ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study) was designed to evaluate the effectiveness of low dose (0.6 mg/kg body weight) compared with a standard dose (0.9 mg/kg) of intravenous alteplase in patients with AIS who fulfill guideline-recommended criteria for thrombolysis treatment.10 Although the ENCHANTED trial failed to meet its primary noninferiority outcome, a prespecified subgroup analysis identified a borderline significant interaction (P=0.052) between prior APT use and alteplase dose on the primary outcome—the conventional binary separation of scores of 2 to 6 that define death or disability on the modified Rankin Scale (mRS).10 We report herein, more details of the balance of benefits and risks of alteplase according to prior APT use and potential modification of effects by use of low-dose alteplase.

Materials and Methods

Patients

The ENCHANTED trial is an international, multicenter, prospective, randomized, open-label, blinded-end point trial that used a 2×2 quasi-factorial design to assess the effectiveness of low- versus standard-dose alteplase in the completed arm and more intensive versus guideline-recommended control of blood pressure in the ongoing arm, full details of which are outlined elsewhere.10 This analysis considers the alteplase dose arm where 3310 patients with a clinical diagnosis of AIS confirmed on brain imaging and fulfilling local criteria for thrombolysis treatment administered within 4.5 hours of symptom onset were randomly assigned to receive low-dose (0.6 mg/kg; 15% as bolus, 85% as infusion during 1 hour) or standard-dose (0.9 mg/kg; 10% as bolus, 90% as infusion during 1 hour) intravenous alteplase. The study protocol was approved by the appropriate ethics committee at each participating center, and written informed consent was obtained from the patient or an appropriate surrogate.

Procedures

Key demographic and clinical characteristics, including the prior use of aspirin or another APT agent, were recorded at the time of enrollment. Stroke severity was measured using the National Institutes of Health stroke scale at baseline, 24 hours, and at day 7 (or earlier, on discharge from hospital). Uncompressed digital images of all baseline and follow-up digital computed tomography, magnetic resonance imaging, and angiogram images were collected in DICOM format (Digital Imaging and Communications in Medicine) on a CD-ROM identified only with the patient’s unique study number and analyzed centrally for any intracranial hemorrhage by independent assessors blinded to clinical data, treatment, and date and sequence of scan. Assessors graded any identified hemorrhage as intracerebral using a range of standard definitions (Materials section in the online-only Data Supplement) and subarachnoid, intraventricular, subdural, or other.

The primary clinical outcome was the combined end point of death or disability at 90 days, defined by scores of 2 to 6 on the mRS. Other efficacy outcomes included an ordinal mRS shift and the combined end point of death or major disability (mRS scores of 3–6) at 90 days. The secondary (safety) outcome was sICH, defined according to several criteria from other studies (Materials section in the online-only Data Supplement).

Statistical Analysis

The association of prior APT on global functional outcome was estimated using ordinal logistic regression after the assumption of proportionality of the odds was confirmed from a likelihood ratio test. Logistic regression models were used to estimate associations for all the other outcomes. Adjustments were made for the prespecified minimization and baseline covariates and additionally for aspects of management during the first 7 days after hospital admission. In patients with and without prior APT, the heterogeneity of alteplase treatment effects was tested by adding interaction terms to the statistical models. 2-sided P values were reported, and P<0.05 was considered statistically significant. The SAS, version 9.3, (SAS Institute, Cary, NC) was used for the analysis.

Results

Baseline Characteristics

These analyses included 3285 patients (38% women; mean age, 66.6 years) in whom the presence or absence of prior APT use was recorded (Figure I in the online-only Data Supplement); 752 (22.9%) patients reporting the use of prior APT at baseline. Those with prior APT were older, and more likely to be of non-Asian ethnicity, had baseline imaging changes indicative of more severe cerebral infarction, and were diagnosed with a presumed cardioembolic or other stroke pathology (Table I in the online-only Data Supplement). Patients on prior APT were also more likely to have associated comorbidity (including hypertension, previous stroke, coronary artery or other cardiac disease, or risk factors, including atrial fibrillation, diabetes mellitus, and hypercholesterolemia) and to be on statin therapy (Table I in the online-only Data Supplement). However, with the exception of a history of hypercholesterolemia and use of statins, there were no baseline imbalances between the use of low-dose or standard-dose alteplase in patients on prior APT (Table). Overall, patients with prior APT were treated more quickly after the onset of symptoms and received a higher bolus alteplase dose, but there were no other significant differences in thrombolysis-associated management (Table II in the online-only Data Supplement).

View this table:
  • View inline
  • View popup
Table.

Baseline Characteristics by Randomized Treatment Among Patients on Prior Antiplatelet Therapy

Prior APT and Outcome

Prior APT was associated with a worse 90-day clinical outcome, whether defined by mRS scores of 2 to 6 (unadjusted OR, 1.38; 95% CI, 1.17–1.63; P<0.001), 3 to 6 (OR, 1.33; 95% CI, 1.13–1.58; P<0.001), or ordinal shift (OR, 1.41; 95% CI, 1.22–1.63; P<0.001), or mortality alone (OR, 1.46; 95% CI, 1.12–1.89; P=0.005; Table III in the online-only Data Supplement). However, after adjustment for the minimization criteria and important baseline variables at the time of randomization, and subsequently for imbalances in management during the first 7 days of hospital admission, there were no significant differences in these outcomes between patients with and without prior APT (Table III in the online-only Data Supplement). Prior APT was also associated with an increased risk of sICH across most definitions (Table IV in the online-only Data Supplement).

Prior APT and Alteplase Dose

Although not significant, low-dose alteplase tended to have more favorable 90-day outcomes in patients on prior APT compared with those without prior APT, defined by mRS scores of 2 to 6 (unadjusted OR, 0.84; 95% CI, 0.62–1.12 versus OR, 1.16; 95% CI, 0.99–1.36, respectively; P-trend, 0.053), 3 to 6 (OR, 0.80; 95% CI, 0.60–1.08 versus OR, 1.10; 95% CI, 0.93–1.30]; P-trend, 0.065; Table V in the online-only Data Supplement), or as an ordinal mRS shift analysis (OR, 0.76; 95% CI, 0.59–0.88 versus OR, 1.07; 95% CI, 0.93–1.23; P interaction, 0.023; Figure 1). Conversely, for those patients without prior APT—77% of the ENCHANTED population—standard-dose alteplase was associated in a trend toward more favorable outcome (Table V in the online-only Data Supplement). Importantly, there was reduced mortality by 5.0% (−0.05 to 9.95) and 1.1% (−1.13 to 3.40) in patients with and without prior APT (P interaction, 0.23) treated with low-dose compared with standard-dose alteplase, but no significant differences in sICH across a broad range of definitions (Figure 2; Table VI in the online-only Data Supplement).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Global functional outcome at 90 days in patients with and without prior antiplatelet therapy by randomized treatment. The figure shows the raw distribution of scores on the modified Rankin Scale (mRS) at 90 days. Scores on the mRS range from 0 to 6, with 0 indicating no symptoms; 1, symptoms without clinical significant disability; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe disability; and 6, death. Unadjusted odds ratios (ORs; and 95% confidence intervals [CIs]) are provided for ordinal shift of mRS between low- and standard-dose intravenous alteplase by patients with and without prior use of antiplatelet therapy and acute ischemic stroke.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Symptomatic intracerebral hemorrhage in patients with and without prior antiplatelet use, by randomized treatment. The figure shows the rates of symptomatic intracerebral hemorrhage (sICH) on follow-up neuroimaging for patients treated with low-dose and standard-dose intravenous alteplase for acute ischemic stroke, overall and for patients with and without prior antiplatelet therapy (APT). Definitions of sICH shown include SITS-MOST (Safe Implementation of Thrombolysis in Stroke Monitoring Study), NINDS (National Institute of Neurological Disorders and Stroke), ECASS2 and ECASS3 (European Cooperative Acute Stroke Study 2 and 3), and fatal. The overall effect is represented by the open diamond for each sICH definition. For subcategories, black diamonds represent point estimates and horizontal lines represent 95% confidence intervals (CIs).

Discussion

These additional analyses of the ENCHANTED trial related to the patient subgroup on prior APT have shown that, albeit not significant, a trend toward more favorable clinical outcomes with low-dose as compared with standard-dose intravenous alteplase, warranting further evaluation in a randomized controlled trial. Patients on prior APT account for at least one quarter of the thrombolysis-eligible AIS population, as indicated by an international stroke thrombolysis registry,2 the United States Get With the Guidelines quality improvement registry,4 and participants in the ENCHANTED trial, and are at significantly higher risk of sICH3 and poor outcome11 compared with other patients who receive alteplase. This figure may increase further with the aging of population and data suggesting benefits of early use of aspirin in reducing the risk of secondary ischemic events after transient ischemic attack or minor ischemic stroke.12

Our findings are consistent with previous studies of patients on prior APT being at greater risk of thrombolysis-associated sICH, in part, related to the greater co-occurrence of other risk variables, such as older age, statin use, cardiac disease, atrial fibrillation, and diabetes mellitus.4,5 Although higher sICH with APT may explain much of the association with worse functional outcome after AIS, the presence of greater comorbidity is also likely to be particularly relevant.13 The Get With the Guidelines registry showed that aspirin monotherapy was associated with increased sICH after adjustment for baseline imbalances (adjusted OR, 1.18; 95% CI, 1.10–1.28).4

The ENCHANTED trial allowed for a randomized assessment of the comparative effects of low-dose versus standard-dose alteplase in patients on prior APT. Concerns of a higher risk of sICH have led to a wide range of doses of intravenous alteplase being used in many Asian countries in relation to perceived risks and affordability of the treatment.9 Although 3 studies—2 registries14,15 and 1 observational16—have specifically evaluated outcomes by dose of alteplase in Asian populations, only Chao et al16 reported a trend toward an adverse effect of prior APT on outcome. In particular, use of clopidogrel or ticlopidine, but not aspirin, was associated with an increased risk of sICH on multivariate analysis. However, only 3.4% and 4.0% of patients in the low- and standard-dose groups, respectively, were on these agents, and no beneficial effect of low-dose alteplase in patients on prior APT was observed.16 Nonetheless, as low-dose alteplase in the ENCHANTED trial was associated with lower sICH, this may be considered an important treatment option in such patients, despite the absence of any clear reduction in sICH in those patients on prior APT.

Some authors have suggested that prior APT may result in less severe strokes, by limiting the size of the occluding thrombus and subsequent risk of embolization,17 improving recanalization,18 or the microcirculation of the ischemic penumbra through inhibition of platelet-derived vasoconstrictors (eg, thromboxane A2),19 and of potential anti-inflammatory and neuroprotective effects.20 Most recently, a retrospective analysis of a large multicenter registry of 10 433 patients indicated better outcomes in those on prior APT after atherothrombotic stroke, but not after cardioembolism or small vessel occlusion, and only in patients without hemorrhagic transformation.21 However, Ricci et al22 found no association of previous aspirin use with baseline stroke severity in the third international stroke trial. Additionally, Pan et al6 did not demonstrate increased recanalization rate in patients on prior APT in their meta-analysis. In ENCHANTED trial, more patients in the prior APT group had atrial fibrillation and a final diagnosis of cardioembolic stroke, features which may suggest a lower efficacy of low-dose alteplase because of proximal vessel occlusion and greater clot burden. Nonetheless, low-dose alteplase was associated with better clinical outcome on shift analysis of 90-day mRS.

On the basis of these current data, many study protocols and guidelines have recommended that APT be avoided for at least 24 hours after the use of alteplase.23 Although higher sICH was seen with de novo use of aspirin at the time of thrombolysis in the ARTIS trial,8 only 3 (0.53%) episodes of sICH (according to the SITS-MOST definition [Safe Implementation of Thrombolysis in Stroke-Monitoring Study]) occurred among 571 patients who also received antithrombotic therapy (antiplatelet or heparin) within the first 24 hours after thrombolysis in the ENCHANTED trial. These numbers are too small to offer a reliable assessment of risk or to assess differences according to variable doses of alteplase. However, the Cochrane review of thrombolysis trials concluded that the odds of mortality increases with early administration of APT; the majority of this risk occurring in the first 24 hours.24

Another important aspect of APT in AIS relates to the type, number, and combination of prior agents for which the data are scarce, but a significant dose response in relation to the number of antiplatelet agents prescribed has been reported.5,6 A higher sICH risk was noted in thrombolysis-treated patients on combination therapy, in particular aspirin and clopidogrel, who were registered in the Virtual International Stroke Trials Archive database.25 Such an association was also noted in the SITS International Stroke Thrombolysis Register3 and the Get With the Guidelines registry cohort where the combination aspirin and clopidogrel were associated with a number needed to harm of 60 compared with 147 for aspirin monotherapy.4 Nonetheless, low number of patients and sICH in all these studies limits the reliability of these data and the recommendations that can be made for clinical practice. Moreover, uncertainty exists over the role of newer antiplatelet agents in the setting of thrombolysis for AIS, although a small pilot phase trial demonstrated the safety of a GP IIb/IIIa (glycoprotein IIb/IIIa) inhibitor with low-dose alteplase.26 Being a pragmatic academic study, ENCHANTED is unable to provide any information about the relation of type, dose, combination, duration, indication, and timing of the last dose of APT before thrombolysis to adverse outcomes, although it would seem reasonable to assume that aspirin monotherapy was the most commonly prescribed antiplatelet regimen used in participating countries.

Other limitations of our study include those related to an open-label trial, despite our efforts to minimize reporting bias, concealment of treatment allocation, rigorous assessment of adverse events, and blinded evaluation of clinical outcomes using established criteria. Because the ENCHANTED trial included patients with generally milder stroke severity with a slightly longer treatment delay from onset than in previous trials1 or registries,27 there may be concerns over the generalizability of these data, whereas imprecision in the estimates of the treatment effect may have arisen from the timing and interobserver variability in scoring of the mRS.28

Conclusions

Our study suggests that the use of low-dose, as compared with standard-dose, intravenous alteplase may be associated with improved clinical outcome in patients who were on prior APT. Therefore, we consider a formal evaluation of low- versus standard-dose alteplase in a randomized controlled trial of patients on prior APT is warranted. In addition, the potential beneficial effects of low-dose alteplase in other patient groups considered at high risk of sICH could be considered.29

Sources of Funding

The study is supported by grants from the National Health and Medical Research Council of Australia, the Stroke Association of the United Kingdom, the Ministry of Health and the National Council for Scientific and Technological Development of Brazil (467322/2014–7 and 402388/2013–5), and the Ministry for Health, Welfare, and Family Affairs of the Republic of Korea (HI14C1985).

Disclosures

Dr Robinson is the Senior Investigator for National Institute for Health Research (NIHR). He receives speaking fees from Bayer and Boehringer Ingelheim and advisory panel fees from Bayer and Daiichi Sankyo. P.M. Bath is a stroke association professor of stroke medicine and NIHR Senior Investigator. He receives advisory panel fees from Athersys, Covidien, Nestle, Phagenesis, and ReNeuron and is an unpaid director of Platelet Solutions. Dr Donnan receives advisory board fees from Boehringer Ingelheim, Bayer, Pfizer, AstraZeneca, Servier, and Sanofi. Dr Lavados receives research funding from AstraZeneca, Bayer, and Boehringer Ingelheim and speaking fees from Bayer. Dr Lindley receives speaking fees from Boehringer Ingelheim, Covidien, and Pfizer. Dr Pontes-Neto receives research funding and speaking fees from Boehringer Ingelheim and Medtronic. Dr Olavarria receives research fees from Clinica Alemana de Santiago and George Institute for Global Health. Dr Ricci receives fees from Boehringer, Bracco, and Medtronic. Dr Woodward works as a consultant for Amgen. Dr Chalmers receives research grants and lecture fees from Servier, and Dr Anderson receives advisory panel fees from AstraZeneca and Medtronic, speaking at seminars for Takeda (China) and Boehringer Ingelheim, and research grant from Takeda (China).

Footnotes

  • Guest Editor for this article was Kazunori Toyoda, MD, PhD, FAHA.

  • ↵* Drs Robinson and Wang are joint first authors.

  • Presented in part at the European Stroke Organisation Conference, Barcelona, Spain, May 10–12, 2016.

  • The sponsors had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to the study data. The corresponding author had final responsibility for the decision to submit the article for publication.

  • The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.116.016274/-/DC1.

  • Received December 3, 2016.
  • Revision received March 1, 2017.
  • Accepted March 13, 2017.
  • © 2017 American Heart Association, Inc.

References

  1. 1.↵
    1. Emberson J,
    2. Lees KR,
    3. Lyden P,
    4. Blackwell L,
    5. Albers G,
    6. Bluhmki E,
    7. et al
    ; Stroke Thrombolysis Trialists’ Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929–1935. doi: 10.1016/S0140-6736(14)60584-5.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wahlgren N,
    2. Ahmed N,
    3. Eriksson N,
    4. Aichner F,
    5. Bluhmki E,
    6. Dávalos A,
    7. et al
    ; Safe Implementation of Thrombolysis in Stroke-Monitoring Study Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke. 2008;39:3316–3322. doi: 10.1161/STROKEAHA.107.510768.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Diedler J,
    2. Ahmed N,
    3. Sykora M,
    4. Uyttenboogaart M,
    5. Overgaard K,
    6. Luijckx GJ,
    7. et al
    . Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41:288–294. doi: 10.1161/STROKEAHA.109.559724.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Xian Y,
    2. Federspiel JJ,
    3. Grau-Sepulveda M,
    4. Hernandez AF,
    5. Schwamm LH,
    6. Bhatt DL,
    7. et al
    . Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator. JAMA Neurol. 2016;73:50–59. doi: 10.1001/jamaneurol.2015.3106.
    OpenUrl
  5. 5.↵
    1. Whiteley WN,
    2. Slot KB,
    3. Fernandes P,
    4. Sandercock P,
    5. Wardlaw J
    . Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904–2909. doi: 10.1161/STROKEAHA.112.665331.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Pan X,
    2. Zhu Y,
    3. Zheng D,
    4. Liu Y,
    5. Yu F,
    6. Yang J
    . Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials. Int J Stroke. 2015;10:317–323. doi: 10.1111/ijs.12431.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Diener HC,
    2. Foerch C,
    3. Riess H,
    4. Röther J,
    5. Schroth G,
    6. Weber R
    . Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol. 2013;12:677–688. doi: 10.1016/S1474-4422(13)70101-7.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Zinkstok SM,
    2. Roos YB
    ; ARTIS Investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet. 2012;380:731–737. doi: 10.1016/S0140-6736(12)60949-0.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Sharma VK,
    2. Ng KW,
    3. Venketasubramanian N,
    4. Saqqur M,
    5. Teoh HL,
    6. Kaul S,
    7. et al
    . Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke. 2011;6:523–530. doi: 10.1111/j.1747-4949.2011.00671.x.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Anderson CS,
    2. Robinson T,
    3. Lindley RI,
    4. Arima H,
    5. Lavados PM,
    6. Lee TH,
    7. et al
    ; ENCHANTED Investigators and Coordinators. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374:2313–2323. doi: 10.1056/NEJMoa1515510.
    OpenUrlPubMed
  11. 11.↵
    1. Grotta JC,
    2. Welch KM,
    3. Fagan SC,
    4. Lu M,
    5. Frankel MR,
    6. Brott T,
    7. et al
    . Clinical deterioration following improvement in the NINDS rt-PA stroke trial. Stroke. 2001;32:661–668.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Rothwell PM,
    2. Algra A,
    3. Chen Z,
    4. Diener HC,
    5. Norrving B,
    6. Mehta Z
    . Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016;388:365–375. doi: 10.1016/S0140-6736(16)30468-8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Thomalla G,
    2. Sobesky J,
    3. Köhrmann M,
    4. Fiebach JB,
    5. Fiehler J,
    6. Zaro Weber O,
    7. et al
    . Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007;38:313–318. doi: 10.1161/01.STR.0000254565.51807.22.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Liao X,
    2. Wang Y,
    3. Pan Y,
    4. Wang C,
    5. Zhao X,
    6. Wang DZ,
    7. et al
    ; Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China Investigators. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke. 2014;45:2354–2358. doi: 10.1161/STROKEAHA.114.005989.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Kim BJ,
    2. Han MK,
    3. Park TH,
    4. Park SS,
    5. Lee KB,
    6. Lee BC,
    7. et al
    . Low-versus standard-dose alteplase for ischemic strokes within 4.5 hours: a comparative effectiveness and safety study. Stroke. 2015;46:2541–2548. doi: 10.1161/STROKEAHA.115.010180.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Chao AC,
    2. Hsu HY,
    3. Chung CP,
    4. Liu CH,
    5. Chen CH,
    6. Teng MM,
    7. et al
    ; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan thrombolytic therapy for acute ischemic stroke (TTT-AIS) study. Stroke. 2010;41:885–890. doi: 10.1161/STROKEAHA.109.575605.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Joseph R,
    2. Han E,
    3. Tsering C,
    4. Grunfeld S,
    5. Welch KMA
    . Platelet activity and stroke severity. J Neurol Sci. 1992;108:1–6.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Demaerschalk BM,
    2. Kleindorfer DO,
    3. Adeoye OM,
    4. Demchuk AM,
    5. Fugate JE,
    6. Grotta JC,
    7. et al
    ; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581–641. doi: 10.1161/STR.0000000000000086.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Rosenblum WI,
    2. El-Sabban F
    . Platelet aggregation in the cerebral microcirculation: effect of aspirin and other agents. Circ Res. 1977;40:320–328.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Riepe MW,
    2. Kaisischke K,
    3. Raupach A
    . Acetylsalicyclic acid increases tolerance against hypoxic and chemical hypoxia. Stroke. 1997;28:2006–2011.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Park JM,
    2. Kang K,
    3. Cho YJ,
    4. Hong KS,
    5. Lee KB,
    6. Park TH,
    7. et al
    ; CRCS-5 Investigators. Comparative effectiveness of prestroke aspirin on stroke severity and outcome. Ann Neurol. 2016;79:560–568. doi: 10.1002/ana.24602.
    OpenUrl
  22. 22.↵
    1. Ricci S,
    2. Lewis S,
    3. Sandercock P
    ; IST Collaborative Group. Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial. Stroke. 2006;37:1737–1740. doi: 10.1161/01.STR.0000226740.29910.91.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Jauch EC,
    2. Saver JL,
    3. Adams HP Jr,
    4. Bruno A,
    5. Connors JJ,
    6. Demaerschalk BM,
    7. et al
    ; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947. doi: 10.1161/STR.0b013e318284056a.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Wardlaw JM,
    2. Murray V,
    3. Berge E,
    4. del Zoppo GJ
    . Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;7:CD000213.
    OpenUrlPubMed
  25. 25.↵
    1. Frank B,
    2. Grotta JC,
    3. Alexandrov AV,
    4. Bluhmki E,
    5. Lyden P,
    6. Meretoja A,
    7. et al
    ; VISTA Collaborators. Thrombolysis in stroke despite contraindications or warnings? Stroke. 2013;44:727–733. doi: 10.1161/STROKEAHA.112.674622.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Pancioli AM,
    2. Broderick J,
    3. Brott T,
    4. Tomsick T,
    5. Khoury J,
    6. Bean J,
    7. et al
    ; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008;39:3268–3276. doi: 10.1161/STROKEAHA.108.517656.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Wahlgren N,
    2. Ahmed N,
    3. Dávalos A,
    4. Ford GA,
    5. Grond M,
    6. Hacke W,
    7. et al
    ; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275–282. doi: 10.1016/S0140-6736(07)60149-4.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Quinn TJ,
    2. Dawson J,
    3. Walters MR,
    4. Lees KR
    . Reliability of the modified Rankin scale: a systematic review. Stroke. 2009;40:3393–3395. doi: 10.1161/STROKEAHA.109.557256.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Whiteley WN,
    2. Emberson J,
    3. Lees KR,
    4. Blackwell L,
    5. Albers G,
    6. Bluhmki E,
    7. et al
    ; Stroke Thrombolysis Trialists’ Collaboration. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15:925–933. doi: 10.1016/S1474-4422(16)30076-X.
    OpenUrl
View Abstract

Jump to

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Back to top
Previous ArticleNext Article

This Issue

Stroke
July 2017, Volume 48, Issue 7
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy
    Thompson G. Robinson, Xia Wang, Hisatomi Arima, Philip M. Bath, Laurent Billot, Joseph P. Broderick, Andrew M. Demchuk, Geoffery A. Donnan, Jong S. Kim, Pablo M. Lavados, Tsong-Hai Lee, Richard I. Lindley, Sheila C. O. Martins, Veronica V. Olavarria, Jeyaraj D. Pandian, Mark W. Parsons, Octavio M. Pontes-Neto, Stefano Ricci, Shoichiro Sato, Vijay K. Sharma, Thang H. Nguyen, Ji-Guang Wang, Mark Woodward, John Chalmers and Craig S. Anderson on behalf of the ENCHANTED Investigators
    Stroke. 2017;48:1877-1883, originally published June 15, 2017
    https://doi.org/10.1161/STROKEAHA.116.016274

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Stroke.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy
    (Your Name) has sent you a message from Stroke
    (Your Name) thought you would like to see the Stroke web site.
  • Share on Social Media
    Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy
    Thompson G. Robinson, Xia Wang, Hisatomi Arima, Philip M. Bath, Laurent Billot, Joseph P. Broderick, Andrew M. Demchuk, Geoffery A. Donnan, Jong S. Kim, Pablo M. Lavados, Tsong-Hai Lee, Richard I. Lindley, Sheila C. O. Martins, Veronica V. Olavarria, Jeyaraj D. Pandian, Mark W. Parsons, Octavio M. Pontes-Neto, Stefano Ricci, Shoichiro Sato, Vijay K. Sharma, Thang H. Nguyen, Ji-Guang Wang, Mark Woodward, John Chalmers and Craig S. Anderson on behalf of the ENCHANTED Investigators
    Stroke. 2017;48:1877-1883, originally published June 15, 2017
    https://doi.org/10.1161/STROKEAHA.116.016274
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Stroke
    • Ischemic Stroke
    • Intracranial Hemorrhage

Stroke

  • About Stroke
  • Instructions for Authors
  • Stroke CME
  • Guidelines and Statements
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 5th Avenue
Suite 1020
Waltham, MA 02451
email: stroke@strokeahajournal.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured